Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, randomized, double-blind, active controlled trial comparing Remicade (infliximab) and Remicade plus azathioprine to azathioprine in the treatment of patients with Crohn's disease naive to both immunomodulators and biologic therapy

Next Previous
Search
Trial Profile

Multicenter, randomized, double-blind, active controlled trial comparing Remicade (infliximab) and Remicade plus azathioprine to azathioprine in the treatment of patients with Crohn's disease naive to both immunomodulators and biologic therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary) ; Azathioprine
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms SONIC
  • Sponsors Centocor; Janssen Biotech

    • Most Recent Events

    • 23 May 2021 Results of a post-hoc analysis from four clinical trials: SONIC, UNITI-1, UNITI-2 and IM-UNITI assessing clinical and endoscopic outcomes of CD patients with non-passable strictures presented at the Digestive Disease Week 2021
    • 13 Oct 2020 Results (n=158) of post-hoc analysis relationship of baseline PRO variables, AP and SF with week 26 clinical remission, PRO2 remission, and corticosteroid-free clinical remission , presented at the 28th United European Gastroenterology Week.
    • 05 Jun 2018 Results of a pooled analysis of ACCENT-I, SONIC, ACT-1, and ACT-2 (n=1205) assessing the association between obesity and response to infliximab, published in the American Journal of Gastroenterology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top